Insider Trading Alert - CNMD, RSG And PLCM Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, July 31, 2014, 62 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $688.80 to $331,041,610.43.

Highlighted Stocks Traded by Insiders:

Conmed (CNMD) - FREE Research Report

Daniels Bruce, who is Director at Conmed, sold 1,600 shares at $39.31 on July 31, 2014. Following this transaction, the Director owned 5,000 shares meaning that the stake was reduced by 24.24% with the 1,600-share transaction.

The shares most recently traded at $38.71, down $0.60, or 1.55% since the insider transaction. Historical insider transactions for Conmed go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 3,000
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 3,000

The average volume for Conmed has been 245,700 shares per day over the past 30 days. Conmed has a market cap of $1.1 billion and is part of the health care sector and health services industry. Shares are down 8.24% year-to-date as of the close of trading on Thursday.

CONMED Corporation provides surgical devices and equipment for minimally invasive procedures and monitoring. The stock currently has a dividend yield of 2.03%. The company has a P/E ratio of 31.5. Currently, there are 2 analysts who rate Conmed a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CNMD - FREE

TheStreet Quant Ratings rates Conmed as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, increase in stock price during the past year, growth in earnings per share, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Conmed Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Voce's Plants Eyes Stockholder Value, Director Battle at Air Methods

Insider Trading Alert - CNMD, GLAD And IPHI Traded By Insiders

Daniel Plants' Voce Fund Returns 5% as Other Activist Investors Struggle

Insider Trading Alert - CNMD, AL And CNBKA Traded By Insiders

6 Medical Device Stocks to Buy If Ted Cruz Is Elected President